Stay updated on Pembrolizumab in HER2+ Gastric Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in HER2+ Gastric Clinical Trial page.

Latest updates to the Pembrolizumab in HER2+ Gastric Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page now shows a 403 Forbidden error with a simple header and a Home link. This replaces the previous study record content for the NCT03615326 entry.SummaryDifference20%

- Check18 days agoChange DetectedThe page revision was updated from v3.6.6 to v3.7.0, indicating a new version of the study record; this reflects a metadata/documentation update rather than a substantive modification to the trial details.SummaryDifference0.0%

- Check32 days agoChange DetectedThe page now reflects software revision v3.6.6, replacing the previous v3.6.5. This indicates a minor platform update rather than a substantive change to trial information.SummaryDifference0.0%

- Check39 days agoChange DetectedAdds new NIH grant year annotations (2026-08-26, 2026-08-18, 2026-08, 2023, 2018) and removes older grant entries (2025-12-11, 2025-11-24, 2025-11), updating the study's funding documentation. These changes reflect updates to funding metadata associated with the study.SummaryDifference0.1%

- Check54 days agoChange DetectedThe page now includes sponsor and IPD sharing information, including links and plan details, as well as references to the study protocol and statistical analysis plan. Expanded keyword and MeSH term metadata for the trial now appears on the page.SummaryDifference100%

- Check61 days agoChange DetectedThe Plain Language Summary section was removed from the page, removing a user-friendly explanation of the study's purpose and key details.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab in HER2+ Gastric Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HER2+ Gastric Clinical Trial page.